 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning Aeras Global TB Vaccine Foundation
|
-
Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
(04/11/2008)
Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) presented a progress update and immunology data from a Phase I Ad35 tuberculosis vaccine study at the biennial "Tuberculosis Vaccines ...
-
Vaccine formulated with Intercells adjuvant IC31 part of a broader collaboration to fight Tuberculosis
(02/18/2008)
Intercell AG announced that a Tuberculosis vaccine, which is currently tested in clinical trials and which contains antigens discovered by Statens Serum Institut formulated with Intercells adjuvant IC31®, will be further developed in a partnership ...
-
Statens Serum Institut, Intercell, and Aeras announce the initiation of a clinical trial for a novel TB vaccine candidate
(12/06/2007)
SSI's novel tuberculosis subunit vaccine HyVac4IC31 (AERAS404) enters phase I clinical trial in BCGvaccinated individuals
Statens Serum Institut (SSI), Intercell, and Aeras announced that SSI's novel prophylactic vaccine HyVac4IC31 (AERAS404) against TB have entered phase I clinical trials in BCGvaccinated individuals. The clinical trial has been initiated at the ...
-
Crucell, AERAS and SATVI Announce Start of Tuberculosis Vaccine Clinical Trial in South Africa
(05/15/2007)
Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) at the University of Cape Town announced the launch of a new Phase I clinical trial of the unique AdVac®-based tuberculosis vaccine, ...
-
Aeras commits further USD$5 million to existing TB research agreement with Crucell
(03/09/2007)
Crucell N.V. announced it will receive up to USD$5 million from Rockville, Maryland-headquartered Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine."This technology, which is ...
-
Crucell and AERAS Announce Start of Tuberculosis Vaccine Clinical Trial
(10/27/2006)
Crucell N.V. announced that it has started the phase I clinical trial of the AdVac®-based tuberculosis vaccine it is developing in partnership with The AERAS Global TB Vaccine Foundation. The clinical trial will be an open-label study that will test ...
-
ACE Biosciences and Aeras Global TB Vaccine Foundation enter tubercolosis vaccine collaboration
(12/22/2005)
ACE BioSciences A/S and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, US, have entered a collaboration whereby ACE BioSciences will support characterization of second-generation BCGbased tuberculosis (TB) vaccines under development ...
-
Crucell and Aeras Announce Progress in TB Vaccine Program
(09/12/2005)
Crucell N.V. and Aeras Global TB Vaccine Foundation announced the initiation of a series of clinical studies for their AdVac®-based TB vaccine. The studies, which follow promising results for the vaccine obtained in animal studies, are scheduled to ...
-
Aeras Receives CDC Funding to Develop TB Vaccine Trial Sites in India
(09/20/2004)
3 year, $2.7 Million Award to Prepare for Testing New TB Vaccines
Aeras Global TB Vaccine Foundation today announced a $925,000 cooperative agreement from the US Centers for Disease Control and Prevention to conduct epidemiologic studies in preparation for clinical trials of new tuberculosis (TB) vaccines in ...
|
|
|
|
|
Top
